Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
In response to the company posting pleasing third-quarter results and boosting guidance, shares of Halozyme Therapeutics (NASDAQ: HALO), a biotech that focuses on making other drugs more effective, jumped 13% as of 1:45 p.m. EST.
Here's an overview of the headline numbers from the quarter.
The upbeat quarterly results enabled management to make a number of positive changes to its full-year guidance:
Source: Fool.com
Halozyme Therapeutics Inc. Aktie
55,02 €
-1,68 %
Überwältigendes Buy-Interesse für Halozyme Therapeutics Inc.: 22 Buy-Einschätzungen ohne eine einzige Sell-Einschätzung.
Ein positives, wenn auch bescheidenes, Potenzial für Halozyme Therapeutics Inc. mit einem Kursziel von 56 € im Vergleich zum aktuellen Kurs von 55.02 €.
